Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Abstract Context The European Association of Urology (EAU) Renal Cell Carcinoma (RCC)
Guideline Panel has prepared evidence-based guidelines and recommendations for the …

Background Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer
(NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage …

The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Background The first interim analysis of the KEYNOTE-564 study showed improved disease-
free survival with adjuvant pembrolizumab compared with placebo after surgery in patients …

Background Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was
approved on the basis of a significant improvement in disease-free survival in the KEYNOTE …

Background The standard of care for locoregional renal cell carcinoma is surgery, but many
patients experience recurrence. The objective of the current study was to determine if …

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …